Publicizing our views and rebuttal to GCR’s August 3 report. For the fiscal year ending March 2026, profits are properly recognized including gains on Asia business stake divestiture; increase in accounts receivable is a reasonable factor due to differences in factoring status, revenue recognition standards, and impact of Asia business divestiture; individual financial statements’ dividend treatment aligns with consolidated accounts. Audit opinion remains unqualified.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-07","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4506-20260807-01.pdf","jir_short_summary":"Publicizing our views and rebuttal to GCR's August 3 report. For the fiscal year ending March 2026, profits are properly recognized including gains on Asia business stake divestiture; increase in accounts receivable is a reasonable factor due to differences in factoring status, revenue recognition standards, and impact of Asia business divestiture; individual financial statements' dividend treatment aligns with consolidated accounts. Audit opinion remains unqualified.","jir_summary":"### Reliability of financial reporting and background of disclosures\nIn response to GCR's claims, we reaffirm our policy to maintain the reliability and transparency of financial reporting. We may take appropriate actions including legal measures. Transactions within key group entities and organizational reorganizations have followed prescribed approval processes, and financial reporting has obtained an unqualified opinion from external auditors.\n\n### Key points of the main criticisms and our views\n1) For the profit for the year ending March 2026, we properly recognize the gain on stake divestiture of 49 billion yen. 2) The increase in accounts receivable is due to reasonable factors such as presence\/absence of factoring, differences in revenue recognition criteria, and the impact of Asia business divestiture, and does not indicate inappropriate revenue recognition. 3) The discrepancy pointed out regarding dividends from SMPS is not inconsistent due to consolidation elimination and alignment of accounting treatment. 4) The accounting audit framework and the auditor's opinion are unqualified.","jir_financial_highlights":"View on key points regarding consolidated results for the fiscal year ending March 2026: Unknown (Unknown)\nGain on sale of Asia business stake: 49,000,000,000 yen (Included as a factor contributing to profit growth)\nDividends recognized from SMPS: 164,500,000,000 yen (Of which 116,200,000,000 yen reduces carrying amount of shares, 48,300,000,000 yen recorded as dividend income)","jir_category":"","jir_hashtags":"#SumitomoPharma, #Disclosure_UPDATE, #ReliabilityOfFinancialReporting","jir_key_figures":"49.0 billion yen: Gain on sale of Asia business stake\n164.5 billion yen: Total dividends from SMPS\n109.5 billion yen: Decrease in related-party shares (reflecting in individual financial statements)","jir_meta_title":"\u3010Sumitomo Pharma\u3011Viewpoints on GCR Report and Financial\u6574\u7406\uff5cAugust 2026","jir_meta_description":"Sumitomo Pharma publishes its views on the GCR report. For the fiscal year ending March 2026, profits are properly recognized by gains on divestiture, accounts receivable increase explained by reasonable factors, and dividend processing alignment; audit opinion is unqualified.","jir_og_title":"Sumitomo Pharma Viewpoints on GCR Report and Financial\u6574\u7406","jir_og_description":"Official Sumitomo Pharma view on the GCR report. Summary of proper recognition of gains on disposition, factors behind accounts receivable increase, consistency of dividend processing, and audit opinion.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-98804","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n